ISRCTN32336114已完成2 期
A phase II trial of sequential treatment with cytoreductive therapy and reduced intensity conditioning allogeneic stem cell transplantation for relapsed/ refractory acute myeloid leukemia, high risk myelodysplasia, or other high risk myeloid malignancies
Barts and the London NHS Trust (UK)0 个研究点目标入组 54 人开始时间: 2007年3月27日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Diagnosis of histologically documented acute myeloid leukemia (AML) (any WHO type), with primary induction failure, or at relapse where the patient is not a candidate or does not wish to proceed to a myeloablative transplant. Also, histologically / cytogenetically documented diagnosis of Myelodysplasia (MDS) (IPSS Int. 2, HR) , or other high risk Myeloid Malignancy where the patient is not a candidate or does not wish to proceed to a myeloablative transplant.
- •2. All acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedures must have resolved to National Cancer Institute (NCI) Common Toxicity Criteria (CTC) (Version 3.0) Grade < 2 (with the exception of chemotherapy-induced alopecia). Surgery must have occurred at least 21 days prior to initiation of treatment.
- •3. Age must be greater than 18 years.
- •4. Last dose of antineoplastic therapy must be more than 14 days from starting treatment, except for hydroxyurea or Low Dose Ara C which may have been administered up to 24 hours prior to first study drug administration for leukoreduction.
- •5. Eastern Cooperative Oncology Group (ECOG) performance status must be 0, 1, or 2.
- •6. Life expectancy of at least 2 months.
- •7. Pregnancy test (females of childbearing potential) Negative.
- •8. Signed informed consent indicating that they are aware of the neoplastic nature of their disease and have been informed of the procedures to be followed, alternatives, potential benefits, side effects, risks, and discomforts.
- •9. Willing and able to comply with scheduled visits, treatment plan, and laboratory tests.
排除标准
- •1. Concurrent therapy with any other investigational agent.
- •2. Pregnant or breastfeeding women. All at-risk female subjects must have a negative pregnancy test within 10 days prior to the start treatment.
- •3. Clinically significant cardiac disease (New York Heart Association, Class III or IV).
- •4. Dementia or altered mental status that would prohibit informed consent.
- •5. Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for this study.
- •6. Current malignancies at other sites, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for five years and are deemed at low risk for recurrence, are eligible for the study.
研究者
相似试验
进行中（未招募）
1 期
Sequential treatment with Cytoreductive therapy & transplant for Relapsed/ Refractory Acute Myeloid Leukemia, High Risk Myelodysplasia,or other High Risk Myeloid MalignanciesRelapsed/ Refractory Acute Myeloid Leukemia, High Risk Myelodysplasia,or other High Risk Myeloid MalignanciesMedDRA version: 14.1 Level: LLT Classification code 10000886 Term: Acute myeloid leukemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1 Level: LLT Classification code 10028532 Term: Myelodysplasia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1 Level: LLT Classification code 10060558 Term: Acute myeloid leukemia recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-000806-64-GBBarts Health NHS Trust54
招募中
2 期
A phase II trial of sequential treatment from cisplatin-etoposide therapy (PE) to irinotecan hydrochloride + amrubicin hydrochloride therapy with concomitant use of G-CSF nartograstim in patients with extensive-stage small cell lung cancer or advanced large cell neuroendocrine carcinoma (LCNEC)Extensive-stage small cell lung cancer and stage IIIB/IV large cell neuroendocrine carcinoma (LCNEC)JPRN-UMIN000006497Department of Respiratory Medicine Kitasato University School of Medicine31
进行中（未招募）
1 期
Phase II clinical trial of palliativ treatment of patients with advanced non-operable gastric carcinoma: FLOT regimen followed by AIO regimen and irinotecan combined with artificial nutrition and physical activity - impact on quality of life and fatigue: FLOTIRI gastric cancer trialAdvanced non-resectable adenocarcinoma of the stomach and the gastro-oesophageal junctionMedDRA version: 15.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-014895-23-DEniversitätsklinikum Erlangen50
进行中（未招募）
1 期
Phase II study of first line treatment of Chronic Graft versus Host Disease with Arsenic TrioxideFirst line treatment of Chronic Graft versus Host Disease in patients having received a first allogeneic stem cell transplantation for a hematological diseaseEUCTR2016-002358-18-FRMedsenic24
已完成
不适用
Phase II study of second-line chemotherapy using CPT-11 plus CDDP in patients with advanced/recurrent gastric cancer (OGSG 0504)Advanced/Recurrent gastric cancer which has no response to S-1JPRN-UMIN000000693Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG)35